Doxorubicin, Cyclophosphamide followed by Paclitaxel vs. 5-FU, Doxorubicin, Cyclophosphamide in locally advanced Breast Cancer
- Conditions
- ocally advanced breast cancer
- Registration Number
- TCTR20170711001
- Lead Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 154
Patients willing to be included in this study.
ï‚· Histopathologically proven invasive ductal carcinoma.
ï‚· No prior chemotherapy, radiotherapy or breast surgery.
ï‚· Patients are required to have Eastern Co-operative Oncology Group (ECOG) performance
status up to scale 2.
ï‚· Female sex.
ï‚· Patients without distant metastasis.
Pregnant or lactating woman.
ï‚· Patients dropped out or lost to follow up before completion of study.
ï‚· Serious concomitant medical illness including severe heart disease, uncontrolled diabetes
mellitus, or hypertension.
ï‚· Life expectancy < 6 months.
ï‚· Male sex.
ï‚· Initial surgery (excluding diagnostic biopsy) of the primary site.
ï‚· Patients with distant metastasis.
ï‚· Patients with double primaries.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Response Before surgery and end of chemotherapy RECIST criteria
- Secondary Outcome Measures
Name Time Method Toxicity After each cycle of chemotherapy The National Cancer Institute‘s ‗Common Terminology Criteria for Adverse Events, v.3.0‘